Syngene International Expects Single-Digit FY27 Revenue Decline, Targets FY28 Growth Return

Market snapshot: Syngene International has lowered its financial outlook for the fiscal year FY27, projecting a single-digit decline in local currency revenue and EBITDA margins in the mid-20s. This revised guidance reflects a year of operational transition and intense cost correction as the company navigates the loss of a major commercial biologics contract. Management anticipates a strong recovery and a return to profitable, sustainable growth from FY28 onwards, supported by cost optimization and a ramp-up in asset utilization.

Data Snapshot

• Consolidated revenue from operations for the first quarter of FY27 declined 15.9% year-on-year to ₹736 crore, down from ₹875 crore in the prior-year quarter.
• The company reported a consolidated net loss after exceptional items of ₹9 crore in the first quarter of FY27, compared to a net profit of ₹87 crore in the same period last year.
• Operating EBITDA margins fell to 12% in Q1 FY27, down from 24% in Q1 FY26, heavily impacted by lower operational revenues and exceptional employee termination costs.

What's Changed

• Previously, management had projected flat revenue growth for the full fiscal year FY27.
• The updated guidance scales down expectations to a low single-digit revenue decline in local currency terms, while keeping full-year EBITDA margins in the mid-20s.

Key Takeaways

• FY27 represents a transitional, cost-optimization phase focused on rebuilding client partnerships.
• The termination of a major large-molecule contract (the Zoetis Librela offtake) remains the primary near-term drag.
• Strategic delay in capitalizing the US Bayview facility prevents high depreciation and overhead expenses from impacting the current P&L.
• The business is targeted to achieve a return to profitable and sustainable double-digit growth starting in FY28.

SAHI Perspective

Syngene International's revised outlook highlights the vulnerability of high-end CRDMO operations to customer concentration. While the Q1 net loss of ₹9 crore reflects immediate stress, management's decision to defer capitalization of the US Bayview facility shows sensible cost defense. Rebuilding commercial momentum and diversifying the client pool will be essential to validating the targeted FY28 growth turnaround.

Market Implications

The lowered guidance sparked immediate market reaction, with the stock sliding roughly 9% to hit its 52-week low. Near-term share price performance is likely to remain muted as investors digest the guidance downgrade and wait for signs of stabilization in the second half of FY27. However, with the company maintaining a strong balance sheet of ₹1,541 crore in net cash, long-term valuation support could emerge as the cost corrections take effect.

Trading Signals

Market Bias: Bearish

We maintain a Bearish near-term bias following a 15.9% decline in Q1 revenue to ₹736 crore and guidance indicating a single-digit revenue decline for the full fiscal year.

Underweight: Biotechnology, CRDMO Services

Trigger Factors:

• Onboarding of new clinical and large-molecule CDMO clients.
• Reduction in operating expenses and successful margin stabilization in H2 FY27.
• Formal operationalization of the US Bayview facility at the end of the year.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian contract research and manufacturing organization (CRDMO) space is facing a temporary divergence. While global shifts under the US Biosecure Act present long-term opportunities, near-term biotech funding constraints and client-specific inventory corrections have caused guidance downgrades. Peers like Laurus Labs have shown stronger execution, whereas platforms like Syngene and Piramal are navigating periodic transitions to diversify away from single large molecule dependencies.

Key Risks to Watch

• Delays in clinical trial pilot conversions or new customer acquisitions.
• Protracted sluggishness in US biotechnology research and development funding.
• Foreign exchange volatility, which already caused a ₹50 crore forex hedge loss in the first quarter.

Recent Developments

Syngene International held its 33rd Annual General Meeting on July 29, 2026, approving a final dividend of ₹1.25 per share. The company finalized its senior leadership transitions, with Siddharth Mittal taking charge as Managing Director and CEO starting July 1, 2026, alongside Abhijit Zichy as the new commercial head, aiming to expand commercial outreach in the US and Europe.

Closing Insight

Although FY27 presents severe transitional pain, Syngene's defensive cost management and solid net cash reserve of ₹1,541 crore provide financial stability. Strategic execution under new leadership will be critical to transforming the current headwinds into the projected FY28 turnaround.

High Performance Trading with SAHI.